ASPIRA WOMEN'S HEALTH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.53 USD | +1.15% |
|
+9.63% | -13.48% |
Financials (USD)
| Sales 2024 * | 10.96M | Sales 2025 * | 19.67M | Capitalization | 43.57M |
|---|---|---|---|---|---|
| Net income 2024 * | -17M | Net income 2025 * | -15M | EV / Sales 2024 * | 3.98 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.22 x |
| P/E ratio 2024 * |
-2.63
x | P/E ratio 2025 * |
-3.42
x | Employees | 64 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aspira Women's Health Inc.
More recommendations
More press releases
| 1 day | +1.15% | ||
| 1 week | +9.63% | ||
| Current month | +13.87% | ||
| 1 month | -3.29% | ||
| 3 months | -22.08% | ||
| 6 months | -35.82% | ||
| Current year | -13.48% |
1 week
3.25
3.63
1 month
2.513.81
Current year
2.515.65
1 year
2.316.75
3 years
2.3194.05
5 years
2.31158.10
10 years
2.31158.10
| Managers | Title | Age | Since |
|---|---|---|---|
Nicole Sandford
CEO | Chief Executive Officer | 54 | 21-02-21 |
Sandra Milligan
PSD | President | - | Mar. 31 |
Torsten Hombeck
DFI | Director of Finance/CFO | 54 | 23-06-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ellen Vos
BRD | Director/Board Member | 68 | 23-05-08 |
| Director/Board Member | 58 | 23-05-08 | |
Jannie Herchuk
CHM | Chairman | 61 | 23-05-08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 3.53 | +1.15% | 7,831 |
| 24-04-17 | 3.49 | +1.16% | 13,727 |
| 24-04-16 | 3.45 | +1.77% | 10,371 |
| 24-04-15 | 3.39 | -1.74% | 10,068 |
| 24-04-12 | 3.45 | +7.14% | 24,393 |
Delayed Quote Nasdaq, April 18, 2024 at 04:30 pm EDT
More quotes
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
3.53
USD
Average target price
3.3
USD
Spread / Average Target
-6.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.48% | 43.08M | |
| -14.19% | 11.48B | |
| +44.16% | 3.3B | |
| -19.90% | 2.01B | |
| -38.37% | 1.99B | |
| -30.21% | 1.42B | |
| +16.18% | 1.02B | |
| -6.11% | 699M | |
| -32.75% | 429M | |
| -52.35% | 354M |
- Stock Market
- Equities
- AWH Stock
